StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) company profile

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.67−0.19 (-1.93%)

Close on Nov 16, 2026Market cap $363.80MP/E –Yield –

About Contineum Therapeutics

Pharmaceutical Preparations, SIC 2834

The company is a clinical-stage biopharmaceutical organization that discovers and develops small molecule therapeutics for neuro-inflammatory and immunological diseases. Its primary proprietary product candidate is PIPE-791, a brain-penetrant inhibitor of the lysophosphatidic acid 1 receptor under clinical investigation for idiopathic pulmonary fibrosis and chronic pain conditions such as osteoarthritis and lower back pain. The business also develops PIPE-307, a muscarinic type 1 receptor antagonist, in partnership with Johnson & Johnson for major depressive disorder and relapsing-remitting multiple sclerosis. It also conducts preclinical discovery targeting other related biological pathways.

The business conducts clinical development internationally, including an ongoing global Phase 2 clinical trial for its lead product candidate with planned enrollment of approximately 324 participants across clinical study sites worldwide. The organization retains worldwide commercial and development rights to its LPA1 receptor programs and broader discovery portfolio, while collaborating globally with Johnson & Johnson on select programs. Specific details regarding its headquarters location or operational facilities are not stated in the text.

Summary of the business section of Contineum Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Contineum Therapeutics, Inc.
Headquarters
San Diego, CA
Address
3565 General Atomics Court, Suite 200 92121
Phone
(858) 333-5280
Employees
51, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
CTNM
Exchange
Nasdaq
IPO date
Apr 8, 2024
Shares outstanding
38M, Jul 24, 2026
Public float
$102.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1855175
CUSIP
21217B100
ISIN
US21217B1008
FIGI
BBG01M27SVP6
Share class FIGI
BBG01M27SWR2
EIN
27-1467257

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Carmine N. StengoneCEO and President, Director19,717
Daniel S. LorrainChief Scientific Officer145,337
Tim WatkinsCMO & Head of Development8,961
John Stephen HealyGeneral Counsel and Corp Sec–
Peter T. SloverChief Financial Officer–
Stephen L. HuhnCMO & Sr VP, Clinical Dev.12,800
Troy A. IgnelziDirector–
Evert B. SchimmelpenninkDirector–
Gines Diego MirallesDirector–
Todd R. BradyDirector–
Sarah BoyceDirector–
Olivia C. WareDirector–
Lori Lyons-WilliamsDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Carmine N. Stengone
President and Chief Executive Officer
$655.62K–$2.29M$450.74K$11.45K$3.41M-30%
Peter T. Slover
Chief Financial Officer
$487.49K–$840.27K$238.87K$11.28K$1.58M–
Timothy R. Watkins, M.D., MSc.
Chief Medical Officer and Head of Development
$359.50K$225.00K$984.56K$176.09K$18.18K$1.76M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 8, 2024
Offer price
$16.00
Securities offered
6,875,000
Gross proceeds
$110.00M
Exchange
Nasdaq
First trading day
Apr 5, 2024
First-day close
$15.40-3.7%
Lock-up ends (est.)
Oct 2, 2024

“The initial public offering price per share is $16.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 51 employees, all of which were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?